Press Release September 19, 2021ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC 0 0 Share
Press Release September 19, 2021ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC 0 0 Share
Company Ticker News September 15, 2021Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year? 0 0 Share
Company Ticker News September 15, 2021U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy 0 0 Share
Company Ticker News September 15, 2021U.S. to pay $2.9 billion for an additional 1.4 million doses of Regeneron's COVID-19 therapy 0 0 Share
Press Release September 14, 2021Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail 0 0 Share
Company Ticker News September 13, 2021Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know 0 0 Share
Company Ticker News September 13, 2021Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript) 0 0 Share
Press Release August 30, 2021Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months 0 0 Share
